Actionable news
All posts from Actionable news
Actionable news in LLY: ELI LILLY & CO.,

Why Cholesterol and Alzheimer’s Could Drive Eli Lilly Shares Much Higher

Eli Lilly and Co. (NYSE: LLY), known as one of the powerhouses in the pharmaceutical industry, has just been given another boost by a key analyst. Credit Suisse sees solid upside in this company as the result of a strong pipeline, with its Alzheimer’s candidate as a potential blockbuster.

Credit Suisse upgraded Eli Lilly to an Outperform rating from Neutral and raised its price target to $105 from $89, implying an upside of 22% from current prices. This valuation was driven by higher Jardiance estimates and higher probability-adjusted sales for several pipeline assets, most notably abemaciclib, anti-CGRP and baricitinib. Accordingly, Credit Suisse raised its EPS estimates to $3.30, $3.58 and $4.10 from $3.25, $3.49 and $3.89 for 2015 through 2017, respectively.

The brokerage firm’s proprietary doctor survey highlights how the impressive EMPA-REG OUTCOME results should...